Gonadorelin

Summary

Gonadorelin is a synthetic decapeptide identical to endogenous GnRH. It is used diagnostically to assess pituitary gonadotropin reserve and therapeutically (pulsatile administration) for the treatment of hypothalamic amenorrhea and hypogonadotropic hypogonadism. Continuous administration paradoxically suppresses the HPG axis. It is also used off-label to preserve testicular function and endogenous testosterone production during exogenous androgen therapy.

Mechanism of Action

Gonadorelin is a synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It binds to GnRH receptors on pituitary gonadotroph cells, stimulating the pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate gonadal steroidogenesis and gametogenesis.

Routes of Administration

Goals & Uses

• Treatment of hypogonadotropic hypogonadism (male)EndocrinologyModerate
• Treatment of hypothalamic amenorrhea / induction of ovulationReproductive EndocrinologyHigh
• Preservation of testicular function during exogenous androgen usePerformance / Andrology (off Label)Low
• Diagnostic assessment of pituitary gonadotropin reserveDiagnosticHigh
• Cryptorchidism treatmentPediatric UrologyModerate

Contraindications

• Conditions exacerbated by LH/FSH stimulation (e.g., hormone-sensitive tumors)OncologicHigh
• Hypersensitivity to gonadorelin or GnRH analoguesAllergy / ImmunologicHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Polycystic ovary syndrome (PCOS) in ovulation induction contextReproductiveModerate

Adverse Effects

• Injection site reactionsLocalCommon
• Multiple gestationReproductiveUncommon
• Anaphylaxis / hypersensitivityImmunologicRare
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Ovarian hyperstimulation syndrome (OHSS)ReproductiveUncommon

Drug Interactions

• Exogenous androgens / anabolic steroidsModerate
• GnRH antagonists (e.g., cetrorelix, ganirelix)High
• DigoxinLow
• Dopamine agonists (e.g., bromocriptine, cabergoline)Low

Population Constraints

• Patients with pituitary tumorsOncologic / EndocrinologicRelative
• Pediatric patients (prepubertal)AgeRelative
• Pregnant womenReproductiveRelative
• Patients with ovarian cysts or enlarged ovariesReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Diagnostic assessment of hypothalamic-pituitary-gonadal axis, Cryptorchidism (intranasal, selected countries), Induction of ovulation in hypothalamic amenorrheaVarious national approvals exist across EU member states; availability varies by country.
• United StatesApprovedApproved: Diagnostic evaluation of pituitary gonadotropin reserve, Induction of ovulation in women with hypothalamic amenorrhea (Lutrepulse; now discontinued as branded product)Factrel (gonadorelin HCl) was FDA-approved for diagnostic use. Lutrepulse pump system was approved for ovulation induction but is no longer commercially available; compounded gonadorelin is used off-label.
• United KingdomApprovedApproved: Diagnostic testing of hypothalamic-pituitary-gonadal function, Induction of ovulation in hypothalamic hypogonadismLicensed products available in the UK; specialist endocrinology or reproductive medicine use.

Approved in various jurisdictions for diagnostic and therapeutic use. In the US, Factrel and Lutrepulse (gonadorelin acetate) have been approved; some formulations have been discontinued. Compounded gonadorelin is used off-label in the US. EU and UK have approved formulations for specific indications.

Evidence & Sources

No sources recorded yet.